Research programme: epigenetic cancer therapies - Aptose Biosciences/Moffitt Cancer Center

Drug Profile

Research programme: epigenetic cancer therapies - Aptose Biosciences/Moffitt Cancer Center

Alternative Names: BET inhibitors - Aptose Biosciences; Bromodomain inhibitors - Aptose Biosciences; MA2 014; MA2-1014

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator H. Lee Moffitt Cancer Center and Research Institute
  • Class Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Myeloproliferative disorders; Solid tumours

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a preclinical studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 03 Dec 2015 Pharmacodynamics data from a preclinical trial in Myeloproliferative disorders released by Aptose Biosciences
  • 01 Dec 2015 Preclinical trials in Myeloproliferative disorders in USA (unspecified route) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top